Lantheus Holdings, Inc. (LNTH) Stock Analysis

Company Overview

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products designed to assist clinicians in the diagnosis and treatment of heart conditions, cancer, and other diseases worldwide. Operating within the Healthcare sector specifically as a Drug Manufacturer in the Specialty & Generic industry, the company focuses on specialized medical solutions rather than mass-market pharmaceuticals. The enterprise maintains a substantial market capitalization of $5.17B while generating annual revenue of $1.54B with an operational workforce of 1193 employees. These valuation and revenue figures indicate that Lantheus holds a significant position in its niche, supported by a robust employee base that facilitates the complex manufacturing and commercialization processes required for specialized medical devices like DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams.

Financial Health

The company reported a revenue of $1.54B for the trailing twelve months, with net income reaching $233.56M and EBITDA standing at $382.31M. The substantial gap between the $1.54B revenue and the $233.56M net income reveals a cost structure where approximately 84.8% of revenue is absorbed by costs of goods sold and operating expenses before arriving at net profit. Lantheus generates free cash flow of $265.57M, which provides the organization with significant financial flexibility to fund operations, service debt, or pursue strategic initiatives without immediate reliance on external financing. The company's profitability is characterized by a gross margin of 61.1%, an operating margin of 19.1%, and a profit margin of 15.2%, indicating that the firm retains more than half of its revenue after direct production costs and maintains healthy operational efficiency. On the balance sheet, the company holds $359.12M in cash against $623.24M in total debt, resulting in a debt-to-equity ratio of 57.19%, which suggests a leveraged position where liabilities exceed equity but are partially offset by significant cash reserves. Liquidity is further supported by a current ratio of 2.70, indicating that the company possesses more than twice the current assets necessary to cover its short-term obligations, thereby ensuring strong short-term solvency. Management effectiveness is reflected in a return on equity of 21.4% and a return on assets of 9.3%, demonstrating that the company generates substantial returns relative to the shareholders' investment and the total asset base employed.

Valuation Assessment

Valuation metrics for Lantheus Holdings, Inc. show a trailing P/E ratio of 22.87 and a forward P/E of 12.39, where the significant difference between these figures implies that the market expects earnings to increase substantially in the coming years compared to the historical performance. The price-to-book ratio stands at 4.62, indicating that the market values the company at a significant premium over its net asset book value, likely reflecting the intangible value of its intellectual property and market position. Alternative valuation metrics include a price-to-sales ratio of 3.35 and an EV/EBITDA of 13.87, suggesting that investors are willing to pay a moderate multiple relative to sales while the enterprise value relative to earnings remains below the trailing P/E. Price volatility context is provided by the 52-week high of $108.91 and the 52-week low of $47.25, with the current trading price sitting at a level that reflects the wide range of recent market sentiment. The beta value of -0.14 indicates that the stock price moves inversely to or with significantly less volatility than the broader market, presenting a unique risk profile compared to typical healthcare equities.

Growth & Income

Revenue growth for the trailing twelve months stands at 4.0%, while earnings growth is listed as N/A, meaning specific year-over-year earnings expansion data is not disclosed in the available records. In the absence of reported earnings growth figures, the relationship between revenue expansion and profit generation remains opaque regarding whether earnings are growing faster or slower than the 4.0% revenue rate. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders and instead reinvests its earnings into growth initiatives, research, and development. The overall growth and income profile is defined by steady single-digit revenue expansion without current income distribution, relying on capital appreciation and operational scaling rather than yield for return generation.